Project Grant R01HL171197

Award Date 7/5/24
Completion Date 4/30/28
Dollars Obligated $1.9M
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boulder, CO 80309, USA
Similar Awards
This $148,568 federal Project Grant awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of inflammation and sex-specific differences in the progression of aortic valve stenosis (AVS). The key objectives are to: 1) delineate how secreted factors from valve cells impact macrophage phenotype and vice versa in a sex-dependent manner, and 2) elucidate sex-specific differences in AVS...
This $600,000 National Science Foundation (NSF) Engineering (CFDA 47.041) project grant award to the University of California, San Diego (UC San Diego) aims to improve the understanding of how sex chromosomes contribute to female-specific aortic valve stenosis progression. The researchers will engineer dynamic hydrogel cell culture platforms to investigate how the X chromosome-linked gene XIST regulates extracellular matrix remodeling and fibrosis in female valve interstitial cells,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to leverage sex-specific anatomical and functional differences to enhance treatment and improve survival outcomes for women with severe aortic stenosis (AS). The $223,750 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, will fund a 2-year research project focused on developing advanced...
This federal Project Grant award, valued at $116,250.00 and provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the development and progression of calcific aortic valve disease (CAVD) among individuals aged 75 and older. The award aims to: 1) examine long-term risk factors for the development of aortic valve calcification (AVC), 2) create population percentiles for AVC in older adults, and 3)...
This federal Project Grant award of $416,625 from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), will support research at Saint Louis University (SLU) to investigate the effects of aging, sex, and hormonal status on atherosclerotic cardiovascular disease (CVD). The key objectives are to: 1) comprehensively map inflammatory cell profiles and cell-cell communication networks in atherosclerotic plaques of young and old male and female mice, including old...
This $750,345 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Pittsburgh. The funding supports research to investigate the role of telomerase reverse transcriptase (TERT) in the osteogenic reprogramming of aortic valve interstitial cells, which can lead to calcific aortic valve disease. The project aims to elucidate the epigenetic and transcriptional changes directed by...
This Project Grant award of $451,000.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research on how sex hormones, particularly estrogen, modulate the mechanotransduction response of chondrocytes in articular cartilage. The University of Texas Southwestern Medical Center will conduct this research to investigate sex-specific differences in chondrocyte mechanotransduction and the role of the mechanosensitive channels Piezo1 and TRPV4, which are key mediators of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $114,938 to Brigham & Women's Hospital Inc. to investigate novel epigenetic mechanisms underlying calcific aortic valve disease (CAVD). The research aims to define the histone code of CAVD, determine downstream translational and post-translational signaling targets, and examine the role of epigenomic modifications on...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, supports research to develop a novel bioprosthetic aortic valve using pulmonary visceral pleura (PVP) tissue. The total award amount is $742,323, with a performance period from December 2024 to November 2028. The research aims to evaluate the mechanical properties, hemodynamics, and long-term durability of the PVP valve, and compare its...
The National Institute on Aging (NIA) awarded a $880,000 Project Grant (CFDA 93.866 - Aging Research) to the University of Delaware to study the effects of daily stress, sleep, and sex hormones on accelerated vascular aging in midlife women. The 2-year project aims to test the hypothesis that greater negative affective responsivity to daily stressors and greater sleep variability are related to more severe declines in endothelial function in premenopausal midlife women, and that these...

HYDROGEL MATRICES TO STUDY THE ROLE OF INFLAMMATION AND BIOLOGICAL SEX ON AORTIC VALVE FIBROCALCIFICATION - ABSTRACT THIRTEEN PERCENT OF ADULTS OVER 75 SUFFER FROM AORTIC VALVE STENOSIS (AVS), A PROGRESSIVE DISEASE THAT LEADS TO ABERRANT COLLAGEN DEPOSITION, LEAFLET STIFFENING, AND EVENTUAL VALVE CALCIFICATION AT LATE STAGES. AVS IS ALSO SEXUALLY DIMORPHIC WITH MEN HAVING A TWO-FOLD HIGHER RISK FOR DEVELOPING DIRECT CALCIFICATION, WHEREAS WOMEN WITH EQUAL DISEASE SEVERITY TEND TO HAVE MORE VALVULAR FIBROSIS PRIOR TO CALCIFICATION. THE MOLECULAR MECHANISMS UNDERLYING SEXUAL DIMORPHISM IN AVS PROGRESSION REMAIN POORLY UNDERSTOOD, BUT GROWING EVIDENCE SUGGESTS AVS IS AN INFLAMMATION-DEPENDENT DISEASE. SEX IS KNOWN TO INFLUENCE THE MAGNITUDE OF THE IMMUNE RESPONSE AND FUNCTION, SO WE PROPOSE TO INVESTIGATE THE ROLE OF INFLAMMATION IN SEX-SPECIFIC VALVE DISEASE PROGRESSION. WE HYPOTHESIZE THAT THREE MAJOR VARIABLES CONTRIBUTE TO DIFFERENCES IN VALVE CALCIFICATION IN MALE AND FEMALE PATIENTS: (1) HEIGHTENED MYOFIBROBLAST ACTIVATION IN FEMALE VALVE CELLS WHEN EXPOSED TO INFLAMMATORY CUES, (2) ELEVATED EXPRESSION OF BONE MINERALIZATION INHIBITORS, SUCH AS OSTEOPONTIN, IN FEMALE VALVE CELLS, AND (3) SEX- SPECIFIC DIFFERENCES IN EPIGENETIC MACHINERY. TO TEST THESE HYPOTHESES, WE WILL DEVELOP SEX-SPECIFIC IN VITRO MODELS OF FIBRO-CALCIFICATION THAT ARE COMPARABLE TO DISEASED VALVE TISSUE. WE WILL THEN INVESTIGATE THE SEX- SPECIFIC ROLE THAT MACROPHAGE AND VALVULAR INTERSTITIAL CELL (VIC) CROSSTALK HAS ON AVS (AIM 1) AND DETERMINE THE ROLE OF EPIGENETICS IN SEX-SPECIFIC REGULATION OF CALCIFICATION REGULATORS (AIM 2). ULTIMATELY, WE AIM TO IDENTIFY SEX- SPECIFIC THERAPIES TARGETED TO VIC POPULATIONS TO SLOW OR HALT AVS DISEASE PROGRESSION (AIM 3).

Posted 7/5/24, 12:00 AM